The growth and transformation suppressor function of promyelocytic leukemia (PML) protein are disrupted in acute promyelocytic leukemia (APL) as a result of its fusion to the RARa gene by t(15;17) translocation. There is signi®cant sequence homology between the dimerization domain of PML and the Fos family of proteins, which imply that PML may be involved in AP-1 activity. Here we show that PML can cooperate with Fos to stimulate its AP-1-mediated transcriptional activity. Cotransfection of PML with GAL4/Fos strongly induced Fos-mediated activation of GAL4-responsive reporters, indicating a functional interaction between Fos and PML in vivo. Deletion analysis of Fos and PML demonstrated that the intact C-terminal domain of Fos (containing the dimerization domain), and the RING-®nger, B1 box and nuclear localization domains of PML are involved in the cooperative activity of Fos and PML. Immunoprecipitation and electrophoretic mobility shift assay showed that PML is associated with the AP-1 complex. PMLRARa was also found to enhance the transcriptional activity of GAL4/Fos. The addition of retinoic acid abrogated the PMLRARa, but not PML-induced stimulation of GAL4/Fos activity in a dose-dependent manner. This study demonstrated that PML is involved in the AP-1 complex and can modulate Fos-mediated transcriptional activity, which may contribute to its growth suppressor function.
Introduction
Cell growth and dierentiation are controlled by several cellular signaling pathways, which mediate the transmission of extracellular signals from the cell membrane to target transcription factors in the nucleus such as AP-1. AP-1 function is mediated by activation of several factors particularly Fos, Jun, activating transcription factors (ATFs), and other related proteins (for review see Angel and Karin, 1991; Karin et al., 1997) . Jun homodimers or Fos/Jun heterodimers bind to the phorbol 12-O-tetradecanoylphorbol 13-acetate (TPA)-responsive element known as the AP-1 site and regulate transcription from promoters bearing this element. Although Jun homodimers are capable of activating the AP-1 transcription, Fos/Jun heterodimers activate the AP-1-responsive target genes more strongly. Fos does not form homodimers and is therefore unable to bind DNA in the absence of Jun (Glover and Harrison, 1995; Hirai et al., 1990; Kouzarides and Zi, 1989) . Altered DNAbinding and transcriptional activity of AP-1 have been shown to mediate its role in cellular growth and dierentiation (Doyle et al., 1997; Kolla and Studzinski, 1993; Muller et al., 1985) . These alterations are mediated by an array of factors such as ligand-activated steroid hormone receptors such as the glucocorticoid receptor and retinoic acid receptor (RAR), which function as regulators of AP-1 transcription (for reviews see Pfahl, 1993; Teurich and Angel, 1995) . These ligand-activated steroid hormone receptors have recently been shown to interact speci®cally with the c-AMP response element binding protein (CREB) binding protein (CBP) (Chakravarti et al., 1996; Kamei et al., 1996) . Because CBP interacts with c-Fos and c-Jun (major components of AP-1) and serves as their coactivator , it has been hypothesized that inhibition of AP-1 transcription by ligand-activated steroid hormone receptors is caused by competition for limited quantities of CBP in the cell (Kamei et al., 1996) .
In acute promyelocytic leukemia (APL), the promyelocytic leukemia (PML) and RARa genes are fused by t(15;17) translation, resulting in expression of the PMLRARa fusion protein (Borrow et al., 1990; De The et al., 1991) . PML encodes a nuclear phosphoprotein with a growth and transformation suppressor function (Mu et al., 1994; Chang et al., 1995; Liu et al., 1995) . PML is a primary target for interferons, and its expression is signi®cantly induced by both classes of interferons (Stadler et al., 1995) . PML protein localizes to distinct subnuclear domains called nuclear bodies (NBs), also known as PML oncogenic domains (PODS), Kr bodies or nuclear dot domains (NDD), which their integrity is disrupted in APL cells because of the expression of the PMLRARa fusion protein (Dyck et al., 1994; Weis et al., 1994; Doucas and Evans, 1996) . Treatment of APL cells with all-trans retinoic acid (ATRA) presumably results in the degradation of PMLRARa through activation of a proteasome pathway and, therefore, rearrangement of the nuclear bodies, which is followed by induction of terminal dierentiation (Yoshida et al., 1996) . In transgenic studies, PMLRARa expression has resulted in impairment of myelopoiesis and initiation of acute leukemia in mice, con®rming the direct contribution of this fusion protein in APL transformation (Early et al., 1996; Brown et al., 1997) .
Structurally, PML contains a cysteine/histidine-rich region that is divided into three domains: RING-®nger, B1 box and B2 box, followed by an a-helical coiled-coil (dimerization) domain and a serine/proline-rich region (De The et al., 1991; Kakizuka et al., 1991) . The presence of the RING-®nger and B-box motifs classi®es PML into a large family of proteins that include transcription regulatory factors and proteins involved in oncogenesis (Freemont et al., 1991; Reddy et al., 1992) . Recent investigations have provided evidence supporting the involvement of PML in the regulation (repression and activation) of transcription. In transient transfection experiments, PML was shown to inhibit transcription from the epidermal growth factor receptor (EGFR) and human multi-drug resistance 1 (MDR1) promoters (Mu et al., 1994) , and is able to repress transcription from GAL4-responsive promoters when directed to DNA via the DNA-binding domain of GAL4, a yeast transcription factor (Vallian et al., 1997) . Conversely, another report indicated that both PML and the translocation fusion product PMLRARa are capable of inducing the transcriptional activity of steroid hormone receptors, and altering their subcellular distribution (GuiochonMantel et al., 1995) . Because, PML does not bind DNA, it is postulated that its eects on transcription are through protein-protein interactions with other factors involved in transcription regulation (Borden et al., 1995) . Supporting the above hypothesis, recent analysis of the solution structure of the PML RING®nger suggests that this region may be involved in protein-porotein interactions (Borden et al., 1996) . Accordingly, the PML-interacting clone 1 (PIC1), a new ubiquitin-like protein, was recently cloned by twohybrid screening. This protein is the ®rst PMLinteracting protein to be identi®ed that is also associated with the PML nuclear bodies (Boddy et al., 1996) . The PMLRARa fusion protein, which retains the cysteine/histidine-rich region, the dimerization domain of PML, and the functional domains of RARa including the DNA-binding, dimerization and ligandbinding domains, functions as a retinoic aciddependent transcription factor (Kastner et al., 1992) . It has been reported that PMLRARa can regulate AP-1 activity in a retinoic acid dose-dependent manner and that the intact RING-®nger motif and dimerization domain of its PML moiety are important for AP-1 regulation (Doucas et al., 1993; Altabef et al., 1996) . However, whether PML is involved in AP-1 transcription is not known, and is the subject of the present study. The integrity of the cysteine/histidine-rich region and dimerization domain of PML are also shown to be required for localization of PML to the nuclear bodies and for its growth and transformation suppressor ability (Le et al., 1996) .
In this study, the eects of PML on AP-1 activity are further investigated. The results demonstrate that PML is functionally associated with the AP-1 complex and modulates its transcription. PML and its mutant form PMLRARa were found to induce GAL4/Fosmediated transcriptional activity, suggesting the presence of a functional interaction between these proteins and Fos, a major component of the AP-1 complex. This functional interaction was found to be dependent on the intact C-terminal domain of Fos and the RING-®nger and B1 box motifs as well as the nuclear localization domain of PML. The enhancing activity of PMLRARa, but not PML, on Fos mediated transcriptional activity is inhibited by ATRA in a dosedependent manner. The functional interaction of PML with Fos and its association with the AP-1 complex, an important factor in cell growth and dierentiation, may contribute to the known function of the PML protein as a growth and transformation suppressor.
Results

Regulation of AP-1 transcription by PML and PMLRARa
A segment in the dimerization domain of PML shows homology to the Fos family of proteins including cFos, Fra-1 and FosB (components of the AP-1 complex) (Kakizuka et al., 1991) , which raises the possibility of PML involvement in AP-1 regulation. To investigate this possibility, the direct eects of PML on AP-1 transcription were ®rst analysed in Cos-1 cells, using an AP-1 target reporter plasmid PK3CAT, which contains three synthetic AP-1 binding sites (Hirai et al., 1990) . Interestingly, expression of PML resulted in about sevenfold induction of chloramphenicol acetyltransferase (CAT) activity from the AP-1 reporter plasmid ( Figure 1a , lane 2). Expression of Fos and Jun, which served as positive controls, also resulted in a strong stimulation of CAT activity as expected (Kouzarides and Zi, 1989) . In control experiments, consistent with the previous reports, expression of PMLRARa resulted in a signi®cant activation of transcription from the AP-1 reporter plasmid in the presence of 1 mM ATRA (Doucas et al., 1993) . The addition of ATRA had no signi®cant eect on the enhancing activity of PML, and did not aect the Fos/Jun-mediated activity of AP-1 transcription.
To investigate whether PML-induced AP-1 activity is mediated by endogenous Fos and Jun proteins, the eects of PML on AP-1 transactivation were further investigated in F9 teratocarcinoma cells, which are virtually AP-1 negative because of the negligible expression of Fos and Jun and therefore serve as a good model for transient transfection studies (YangYen et al., 1990) . As shown in Figure 1b , whereas expression of either Jun or Jun/Fos resulted in a marked stimulation of transcription from the AP-1 target promoter, PML shows no signi®cant eect. Interestingly, co-expression of PML and Jun/Fos, but not Jun alone, resulted in a signi®cant stimulation of the AP-1 target promoter (Figure 1b ; compare lanes 5 and 6). Under the same condition, cotransfection of Fos alone or together with PML did not have a signi®cant eect on the AP-1 activity in F9 cells. No stimulation of CAT activity by PML, Fos/Jun, or both was observed in cotransfection experiments using the parental reporter vector lacking the AP-1 sites (data not shown). Together, these results indicate that PML can regulate AP-1 transcription by inducing its Fos/ Jun-mediated transcriptional activity.
To further examine the eect of PML on AP-1-mediated transcription, we studied the eects of PML on a natural promoter element that responds to AP-1. The human collagenase promoter is the ®rst and bestcharacterized promoter whose transcription is activated by Fos and Jun (Angel et al., 1987) . Therefore, the eects of PML were examined on a collagenase-CAT construct (residues 773 to +63 of the human Figure 1c demonstrate that cotransfection of the collagenase-CAT reporter with PML signi®cantly increased the promoter activity (fourfold). As expected cotransfection of Fos, Jun or both also resulted in a signi®cant stimulation of the promoter activity. Consistent with the above results, cotransfection of PML with Fos and Jun further increased (about ®vefold) transcription from the collagenase-CAT promoter. This data further demonstrated that the PML mediated activation of AP-1 transcription is owed through its cooperation with Fos and Jun.
PML and PMLRARa induce Fos-mediated transcriptional activity
Given the signi®cant induction of Fos/Jun-, but not Jun-mediated transcriptional activity of AP-1 by PML in F9 cells (Figure 1b ), we were promoted to analyse the presence of a possible functional interaction between PML and Fos. Fos does not bind DNA by itself, rather, it requires dimerization with Jun for its DNA-binding and transcriptional activity (Kouzarides and Zi, 1989) . However, when targeted to DNA through a heterologous DNAbinding domain (DBD) such as that of GAL4, Fos can strongly stimulate transcription from GAL4 target promoters (Sutherland et al., 1992) . The GAL4/Fos fusion protein has also been used in several studies to investigate the functional interaction of Fos with other proteins such as CBP (Sutherland et al., 1992; Brown et al., 1995) . Therefore, a similar plasmid encoding the Fos protein linked to the DBD of GAL4 (amino acids 1 ± 47) (Sutherland et al., 1992) was used to analyse the activity of the GAL4/Fos fusion on GAL4 target reporter plasmids in the presence of PML or PMLRARa. Cos-1 cells were cotransfected with the GAL4 target CAT reporter plasmid PUAS10CAT (Cousens et al., 1989) and GAL4/Fos together with or without PML or PMLRARa. As shown in Figure 2 , expression of either PML or PMLRARa with GAL4/Fos resulted in a marked induction of CAT activity from the GAL4 target promoter (compare lanes 3 and 4 with lane 2 in Figure 2 ). Under the same conditions, RARa had no eect on GAL4/Fos activity (lane 5). The addition of 1 mM ATRA had no signi®cant eect on the stimulatory eect of PML, but completely abolished the PMLRARa eects (compare lanes 4 and 9 in Figure 2 ). Cotransfection of a short isoform of PML (Mu et al., 1994) also showed the same eects on the GAL4/Fos-mediated transcriptional activity. Expression of either PML, PMLRARa or Fos (without the GAL4 DNA-binding domain) had no eect on the basal activity of the GAL4 target reporter plasmid.
No stimulation of CAT activity was observed when GAL4/Fos was cotransfected with the parental CAT reporter plasmid PLSO10CAT without the GAL4-binding sites (Cousens et al., 1989) in the absence or presence of PML or PMLRARa, indicating the speci®city of the modulation of GAL4/Fos activity by these proteins (data not shown). Similar results were observed in cotransfections with a dierent GAL4 target CAT reporter construct, G5E1BCAT (Sutherland et al., 1992) , or when cotransfections were repeated in U2OS human osteosarcoma cells (data not shown). Together these data indicate the presence of a functional interaction between PML or PMLRARa and Fos and show that the eects of PMLRARa, but not PML, are dependent on the presence of retinoic acid.
Induction of Fos transactivation by PMLRARa can be diminished by retinoic acid in a dose-dependent manner
Because the eect of PMLRARa on Fos was completely abolished after the cells were treated with 1 mM ATRA, it was of interest to determine whether this eect is concentration-dependent. Accordingly, the eects of ATRA concentrations ranging from 10 75 ± 10 710 M on the modulation of GAL4/Fos activity by PMLRARa were investigated. As shown in Figure 3a , incubation of Cos-1 cells, cotransfected with GAL4/ Fos and PMLRARa, with dierent concentrations of ATRA resulted in a retinoic acid-dependent inhibition . Cells were incubated in the presence or absence of 1 mM ATRA (see Materials and methods). Transfection eciency in each experiment was monitored as described in the legend to Figure 1 . The CAT activities were calculated relative to the activity of the GAL4-responsive reporter plasmid in the presence of GAL4 DBD, GAL4 (1 ± 147), from three independent experiments and presented as mean+s.e.m. A schematic representation of the GAL4-responsive reporter plasmid is shown. TK and GF represent, thymidine kinase minimal promoter and GAL4/Fos, respectively of PMLRARa-induced transcriptional activity of GAL4/Fos from the GAL4-responsive CAT reporter plasmid PUAS10CAT. The highest inhibition was achieved at a concentration of 10 77 M ATRA, with no further increase at higher concentrations.
It was recently reported that ATRA induces a rapid degradation of PMLRARa in NB4 cells (an APLderived cell line expressing PMLRARa) and therefore restores the normal staining pattern of the PML nuclear bodies (Yoshida et al., 1996) . To investigate whether the inhibition of PMLRARa-mediated induction of GAL4/Fos activity in the presence of ATRA is caused by its degradation by a similar mechanism, the expression of PMLRARa in Cos-1 cells following incubation with dierent concentrations of ATRA for 24 h was monitored by Western blotting. As shown in Figure 3b , retinoic acid had no signi®cant eect (although slightly reduced) on the level of PMLRARa protein, suggesting that abolition of the stimulatory eects of PMLRARa on GAL4/Fos by retinoic acid is not caused by degradation of the PMLRARa protein.
Identi®cation of domains of PML and Fos necessary for their functional interaction
To locate the domains of PML and Fos that mediate their functional interaction, a series of GAL4/Fos mutants linked to the GAL4 DNA-binding domain were used in cotransfection experiments. These GAL4/ Fos mutants were cotransfected into Cos-1 cells with the GAL4-responsive CAT reporter plasmid PUAS10CAT, with or without PML. As shown in Figure 4a , consistent with the above results, cotransfection of GAL4/Fos with PML resulted in a marked induction of transcriptional activity (see also Figure  2 ). Expression of PML had no signi®cant eect on the activity of the mutants carrying only the N-terminal domain of Fos, GAL4/Fos (1 ± 81) and GAL4/Fos (1 ± 142), containing Fos amino acids 1 ± 81 and 1 ± 142, respectively. The low activity of GAL4/Fos (1 ± 142), which is due to the presence of an inherent inhibitory domain referred to as ID1 (Brown et al., 1995) , was slightly reduced in the presence of PML. Interestingly, the activity of a C-terminal half mutant of Fos containing the dimerization domain (bzip) and the adjacent C-terminal sequences, GAL4/Fos (143 ± 380), was signi®cantly induced in the presence of PML at a level comparable with that of the GAL4/Fos construct (compare lanes 5 and 2 in Figure 4a) . Removal of the dimerization domain of Fos, signi®cantly reduced, but did not abolish, the Fos/ PML interaction (compare lanes 5 and 6 in Figure  4a ). Further dissection of the sequences downstream of the dimerization domain did not completely eliminate the PML eects. This indicates that the intact C-terminal domain of Fos is involved in its functional interaction with PML and that the sequences of the dimerization domain, amino acids 143 ± 209, are most important for this interaction.
The sequences spanning the cysteine/histidine-rich (RING-®nger and B boxes) and coiled-coil (dimerization) domains of PML have been shown to be involved in dimerization with PML and PMLRARa, localization to the PML nuclear bodies and transcriptional regulatory activity (Guiochon-Mantel et al., 1995; Le et al., 1996; Perez et al., 1993; Vallian et al., 1997) . To investigate whether these regions are involved in Fos/ PML functional interaction, a series of deletion mutants of PML were used in cotransfections with GAL4/Fos and PUAS10CAT (GAL4-responsive reporter plasmid) in Cos-1 cells. As presented in Figure  4c , deletion of the proline-rich region of PML (PMLpro-) did not aect PML stimulatory eects on Fos activity. By contrast, further removal of the RING-®nger motif (PMLpr-) or RING-®nger motif plus the B1 box region (PMLprb1-) almost completely abolished the PML eects, indicating the requirements of the RING-®nger motif, B1 box region, or both for PML/Fos cooperation. Deletion of the dimerization domain of PML (PMLdim-) only marginally reduced, as did a deletion in the serine/proline-rich region (PMLsp-) of the protein. Interestingly, deletion of the nuclear localization domain of PML eliminated its enhancing eects on Fos activity, suggesting the necessity of translocation of PML into the nucleus for its functional interaction with Fos. Together these data demonstrate that PML/Fos functional interaction requires the nuclear localization domain and the RING-®nger motif of PML as well as the intact Cterminal domain of Fos.
PML does not directly interact with Fos or Jun
The results discussed above indicate that PML functionally interacts with Fos and that this interaction appears to be speci®c as it involves the RING-®nger/B-box domain of PML and the Cterminal domain of Fos. This functional interaction was further examined using an immunoprecipitation assay. PML was transiently overexpressed in HeLa cells, and the nuclear extracts were prepared as described in the Materials and methods section. The nuclear proteins were subjected to immunoprecipitation using a polyclonal anti-PML antibody (He et al., 1997 ). The precipitated proteins were then absorbed to protein-A agarose and washed extensively. The associated proteins were eluted with high salt (420 mM KCl) in nuclear extraction buer (see Materials and methods) and used in electrophoretic mobility shift assay (EMSA). In this assay anti-Jun antibody (a-Jun) was used as positive control and preimmunized rabbit serum was used as negative control. As shown in Figure 5a , anti-PML antibody (a-PML), but not the control serum, is capable of coprecipitating AP-1 activity. As expected, the antibody against Jun is capable of ecient coprecipitation of the AP-1 activity. The speci®city of the bands was investigated by oligonucleotide competition assay as shown in lanes 4 and 5 of Figure 5a . This result shows that PML is associated with the AP-1 complex in vivo and together with the above ®ndings may suggest that this association involves Fos, Jun or both. We next examined the direct interaction of PML with Fos and Jun. Using an in vitro transcription/ translation system (Promega, Corp., Madison, WI), Fos, Jun and PML proteins were produced and labeled with 35 S-methionine. The labeled proteins were subjected to immunoprecipitation using the anti-PML antibody (see Materials and methods). The ATF2 protein, which is associated with Jun, was also translated in vitro and included in the experiment as a possible factor that might mediate PML association with the AP-1 complex. As shown in Figure 5b , whereas PML protein was eciently precipitated with the anti-PML antibody, no coprecipitation of Jun, Fos, or ATF2 was observed. We have also performed a glutathione S-transferase (GST) pull-down assay using GST-PML protein immobilized on glutathione agarose beads and 35 S-labeled Fos, Jun and ATF2 proteins but failed to detect a direct interaction between these proteins and PML (data not shown). Therefore, it can be concluded that PML is not directly associated with Fos and Jun or ATF2 and that the association of PML with the AP-1 complex and its functional interaction with Fos might be mediated through other or as-yet-unknown factors.
Evidence for the association of PML with the AP-1 complex
To further investigate the in vivo association of PML with the AP-1 complex, an EMSA was performed on the nuclear extracts from HeLa cells. As shown in Figure 6 , incubation of the nuclear extracts with the labeled AP-1 binding site probe produced a speci®c complex. The speci®city of the complex was determined by oligonucleotide competition assay and with speci®c and nonspeci®c antibodies. The speci®c binding was signi®cantly reduced in the presence of 500-fold molar excess of the wild-type cold probe (lane 4 in Figure 6 ) and completely competed out in the presence of 1000-fold wild-type cold probe (lane 2), but not with 1000-fold molar excess of mutated cold probe (lane 5). The presence of Fos in the complex was veri®ed by the addition of anti-Fos antibody (a-Fos, lane 8). Interestingly, the addition of a puri®ed anti-PML antibody (a-PML, lane 7), but not the preimmunized serum (control, lane 6) or an unrelated antibody such as anti-GAL4 antibody (a-GAL4, lane 9), resulted in supershift of the low mobility portion of the AP-1 complex. These data together with the above ®ndings 
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Non-specific binding -Free probe Figure 6 Association of PML with the AP-1 complex. EMSA using nuclear extracts from HeLa cells. The experiments were performed by incubating HeLa nuclear extracts with a labeled double-stranded oligonucleotide probe containing one AP-1 binding site (see Materials and methods for details). In competition assays, 1000-fold or 500-fold molar excess of wildtype probe (wCold, lanes 2 and 4) and 1000-fold molar excess of mutated probe (mCold, lane 5) were used. In the supershift experiments, anity puri®ed PML antibody (a-PML), anti-Fos antibody (a-Fos) and anti-GAL4 antibody (a-GAL4) (lanes 7 ± 9) were used as indicated. Rabbit pre-immune serum was used as control (lane 6). The speci®c AP-1 DNA-binding, nonspeci®c binding, free probes and supershifted PML are indicated suggest that PML is associated with the AP-1 complex and that this association is mediated through an intermediary factor which may involve (or interact with) the Fos protein.
Discussion
The results presented here demonstrate that PML is functionally associated with the AP-1 complex. This functional interaction appears to be speci®c because unique domains of PML and Fos are necessary for their cooperative eects on AP-1-mediated transcriptional activation. In this study, PML was found to regulate AP-1 transcription in the presence of Fos and Jun. Functional analysis using a GAL4/Fos fusion construct showed that PML can positively cooperate with Fos and signi®cantly induce its transcriptional activity. The results also indicate that the t(15:17) fusion product PMLRARa enhances Fos-mediated transcriptional activity. However, the eects of PMLRARa, but not of PML, on Fos activity are diminished in the presence of ATRA in a dosedependent manner.
The AP-1 function is mediated by several mechanisms that can be classi®ed mainly as those that increase the expression and abundance of AP-1 components and those that induce their activity or AP-1 DNA-binding (for review see Angel and Karin, 1991) . Factors associated with the AP-1 complex mainly consist of the Fos (c-Fos, FosB, Fra1 and Fra2), Jun (c-Jun, JunB and JunD), and ATF (ATF2, ATF3/LRF) families of proteins (Karin et al., 1997) . Several new proteins recently have been identi®ed as being associated with the AP-1 components including Maf and the neural retina-speci®c gene product, Nrl which can bind to the AP-1 site and form heterodimers with Fos and Jun (Curran and Kerppola, 1996) . Among the Maf proteins, Maf B, Maf F, Maf G and Maf K form heterodimers with Fos but not with Jun (Kataoka et al., 1994) . Moreover, several proteins have been found to function as co-activators for AP-1 components such as CBP and the Jun-activation-domain-binding protein (JAB1) Claret et al., 1996) . The results from this study show that the eects of PML on AP-1 activity most likely occur through the AP-1 component(s) or associated factor(s) that are involved in the regulation of their activity rather than directly through the AP-1 site. Expression of PML in Cos-1 cells enhanced the activity of the AP-1 target reporter plasmid, but no activation was observed in F9 cells, which are virtually negative for Fos and Jun proteins (Yang-Yen et al., 1990) . This ®nding suggests the necessity of Fos and Jun proteins for the PML-induced activation of AP-1 transcription. The fact that PML can induce GAL4/ Fos-mediated transcriptional activity con®rms the above ®nding and shows the presence of a functional interaction between Fos and PML. However, because our attempts to detect a physical interaction between PML and Fos were unsuccessful, the PML-induced stimulation of GAL4/Fos activity is likely achieved indirectly through activation or stabilization of a secondary factor or factors involved in Fos transactivation (Karin et al., 1997) . A similar functional interaction also has been reported for the retinoblastoma tumor suppressor protein pRb. It has been shown that although pRb does not directly interact with the transcription factor Sp1, it can eciently activate GAL4/Sp1 transactivation (Kim et al., 1992) .
CBP recently has been shown to speci®cally interact with Fos and Jun, functioning as a co-activator and hence stimulating AP-1 transcription Kamei et al., 1996) . The C-terminal domain of Fos contains three Fos activation modules (see Figure 4a) , which have been shown to cooperate with each other to activate transcription (Brown et al., 1995) . These regions mediate direct interaction of Fos with the TATAbox-binding protein (TBP) and the transcription factor IID (TFIID) complex, which is an important step for activation of transcription by Fos (Brown et al., 1995) . This region of Fos has also been shown to mediate its speci®c interaction with CBP . In the present study, the intact C-terminal domain of Fos (amino acids 143 ± 380) was found to be important for its functional interaction with PML (see Figure 4a ). Thus, although the exact mechanism of the stimulation of GAL4/Fos activity by PML is not clear at this point, it can be postulated that PML may stabilize interaction of Fos with its co-activator CBP, the TBP/TFIID complex, or both, which involve its Cterminal domain. However, the possible sequestration of a co-inhibitor of Fos by PML cannot be ignored (Brown et al., 1995) .
Our study demonstrated that PMLRARa also strongly stimulates the transactivation function of GAL4/Fos in the absence of ATRA, which can be completely abolished in the presence of ATRA (10 77 M, see Figure 3a ). This ®nding indicates the presence of a functional interaction between PMLRARa and Fos. PMLRARa retains the RING®nger, B-box and dimerization domains of PML as well as the DNA-binding and ligand-binding/dimerization domains of RARa. Deletion analysis of PML showed that the RING-®nger and B1 box motifs of PML are essential for its functional interaction with Fos ( Figure 4c ). Since these regions are retained in PMLRARa, they may also mediate Fos/PMLRARa functional interaction. The mechanism of inhibition of PMLRARa's eect on Fos activity by ATRA is currently unknown. It recently has been shown that ligand-activated steroid hormone receptors including RARa can interact directly with CBP through their ligand-binding/dimerization domain and inhibit the AP-1 activity possibly by competing for the limited amount of CBP in the cell (Chakravarti et al., 1996; Kamei et al., 1996) . This is evident for the eect of RARa on Fos activity in the presence of retinoic acid (compare lanes 5 and 10 in Figure 2) . Therefore, it can be speculated that the possible binding of the mutant receptor to CBP through the ligand-binding/ dimerization of its RARa moiety in the presence of ATRA may have aected its functional interaction with Fos (Kamei et al., 1996) . Experiments analysing the functional and physical interaction of PML and PMLRARa with CBP are now underway.
In contrast to the abolishment of its stimulatory eects on Fos activity by ATRA, PMLRARa activates transcription from AP-1 site (Doucas et al., 1993, and Figure 1a) in the presence of ATRA. Although the exact mechanism of PMLRARa regulatory eect is not clear, these two observations may point to the same conclusion indicating the involvement of PMLRARa in AP-1 regulation, but in two dierent experimental systems. In the case of AP-1 response element, the eects of PMLRARa were examined in the context of other cellular factors which directly or indirectly involved in AP-1 transcription. Whereas, in the case of GAL4/Fos, the heterologous DNA-binding domain (GAL4 DNA-binding domain) and response element (GAL4-binding site) were used. Thus the eects of those endogenous cellular factors competing for DNAbinding were eliminated.
The biological relevance of the functional interaction of PML and PMLRARa with Fos cannot be fully elucidated from the present study and obviously requires more investigation. However, the increase in DNA-binding and/or activation of AP-1 components (mainly Fos and Jun) has been shown to be associated with growth and dierentiation of several cell lines including leukemia cells such as HL-60 and U937 (Doyle et al., 1997; Kolla, 1993; Muller et al., 1985) . As an example, in HL-60 cells the monocytic dierentiation induced by TPA or vitamin D3 is paralleled by increased AP-1 activity and by elevated c-Jun expression (Kolla, 1993) . Furthermore, the adenovirus E1A protein, which induces immortalization and activation of cell-cycle progression, can repress the AP-1 activity and Fos-mediated transactivation . The induction of Fos/Jun-mediated AP-1 transcription activity in response to PML as shown in this study may therefore correlate with its demonstrated growth suppressor function. Interestingly, deletion analysis showed that the RING-®nger and B1 box motifs of PML, which are required for its inhibition of neu-induced transformation and localization in PODs (Mu et al., 1994; Le et al., 1996) , are also essential for its induction of Fos-mediated transcriptional activity. These observations could provide further evidence to support the hypothesis that disruption of PML's function as a result of its fusion to RARa may be responsible for the increase in proliferation and appearance of the leukemia phenotype in APL (Mu et al., 1994) . Further investigations are necessary to identify the site of interaction of PML with the AP-1 complex and factors by which PML mediates its stimulatory eects on Fos-mediated transcriptional activity.
Materials and methods
Plasmids
GAL4/Fos and GAL4/Fos mutants were constructed by inframe fusion of their coding sequences to the sequences coding for the DBD of GAL4 in the expression plasmid pHKG4, as previously described (Sutherland et al., 1992) . This plasmid contains an SV40 promoter/enhancer upstream of the GAL4 DBD (amino acids 1 ± 147). PML and PMLRARa (long isoforms) cDNAs were expressed from pSG5 under the control of the SV40 promoter (De The et al., 1991) . RARa cDNA was also expressed from pSG5 (Petkovich et al., 1987) . PML deletion mutants were constructed as described in our previous report (Le et al., 1996) and expressed in pSG5 driven by the SV40 promoter. The c-Fos and c-Jun cDNAs were expressed under the control of the SV40 promoter from pHK (base vector for pHKG4) vector which lacks the GAL4 DNA-binding domain, as previously described (Sutherland et al., 1992) . The GAL4-responsive CAT reporter plasmids, PUAS10CAT and G5E1BCAT, contain three GAL4-binding sites in front of the thymidine kinase (TK) minimal promoter and ®ve GAL4-binding sites in front of the Epstein-Barr virus (EBV) minimal promoter linked to the CAT gene, respectively, as previously described (Sutherland et al., 1992) . PLSOCAT, the base vector of PUAS10CAT, which lacks the GAL4-binding sites, was used as a negative control. The AP-1 CAT reporter plasmid (PK3CAT) contains three AP-1 sites upstream of the thymidine kinase minimal promoter linked to the CAT gene (Hirai et al., 1990) . The collagenase promoter construct contains bases 773 to +63 of the human collagenase gene fused next to the CAT DNA coding sequence, as previously described .
Cell culture, transfection and CAT assay
Cos-1, F9, HeLa and U2OS cells were maintained in Dulbecco's Modi®ed Eagle's Medium (DMEM) supplemented with 10% fetal calf serum (FCS), 100 units/ml penicillin and 100 mg/ml streptomycin (GIBCO/BRL, Gaithersburg, MD), at 5% CO 2 /378C. Cells were transfected at semicon¯uence (60 ± 80%, Cos-1 and U2OS) and 30% con¯uence (F9) using a calcium phosphate coprecipitation method (Wigler et al., 1978) . Cells were transfected with a total of 20 mg DNA containing 4 mg of the CAT reporter plasmid; 2 mg of pCH110, the bgalactosidase expression plasmid (Pharmacis Biotech, Inc., Piscataway, NJ) and the amounts of expression plasmid indicated in the legends to the Figures. The total amount of DNA was adjusted to 20 mg with sonicated denatured salmon sperm DNA, and pSG5 plasmid, which contains the SV40 promoter, to maintain the concentration of promoter constant. Approximately 16 h after transfection, the precipitate was washed, and cells were fed with fresh medium for an additional 24 h. In the case of treatment with ATRA at concentrations indicated in the Figure legends or the same volume of ethanol (the vehicle for ATRA), cells were fed with DMEM containing 10% charcoal/dextran treated FCS (HyClone Laboratories, Logan, UT) for 24 h. Cells were harvested and lysed as described (Sambrook et al., 1989) . The amount of extracts used for CAT assays were normalized with respect to the bgalactosidase activity. b-galactosidase and CAT assays were performed as described (Sambrook et al., 1989) . Acetylated and nonacetylated chloramphenicol were resolved on thin-layer chromatography and detected by autoradiography. The CAT activities were quantitated using a phosphoimager. All transfections were repeated a minimum of three times and the mean+standard error of mean was calculated. A typical diagram of each CAT assay is presented. PML was transiently overexpressed in HeLa cells by adenovirus-mediated gene transfection using Ad-PML, as previously described (He et al., 1997) .
Electrophoretic mobility shift assay
For preparation of nuclear proteins, HeLa cells at 80 ± 90% con¯uence (10-cm dishes) were washed three times in phosphate-buered saline (PBS) containing 1 mM phenylmethylsulfonyl¯uoride (PMSF), harvested and collected in Eppendorf tubes. Cells (approximately 1610 7 ) were washed again in wash buer (20 mM HEPES, pH 7.9; 2 mM DTT; 2 mM MgCl 2 ; 1 mM PMSF; 2 mg/ml Leupeptin; 1 mg/ml Aprotinin), and lysed in wash buer containing 0.2% Triton X-100 by incubation on ice for 10 min. Nuclei were then collected by centrifugation at 13 000 r.p.m. at 48C for 10 min. The nuclei were resuspended in 50 ml of nuclear extraction buer (20 mM HEPES, pH 7.9; 2 mM MgCl 2 ; 2 mM DTT; 420 mM KCl; 25% Glycerol; 1 mM EDTA and protease inhibitors as in wash buer) and incubated on ice for 20 min. Cellular debris was removed by centrifugation at 13 000 r.p.m. for 5 min at 48C. Protein concentration was determined using the protein assay reagent (Bio-Rad Laboratories, Richmond, CA). The protein/DNA interaction assay was performed by preincubating 5 mg of nuclear proteins in a binding buer (4% Ficoll 400; 20 mM HEPES pH 7.9; 2 mM MgCl 2 and 1 mg of salmon sperm DNA; the ®nal concentration of KCl in the reaction mixture was adjusted to 100 mM) for 10 min at room temperature in a total volume of 19 ml. In each reaction, 10 fmol (1 ml) of labeled probe was then added and the reaction was incubated at room temperature for an additional 30 min. The protein/ DNA complexes were resolved in a 4% native polyacrylamide gel in 0.25 TBE (44.5 mM Tris-HCl, 44.5 mM boric acid, 1 mM EDTA). The wild-type AP-1 oligonucleotide probe was made by annealing the following oligonucleotides: 5'-ACCAGCTGACTCAGATGTCCTAC-3'; 5'-ACGTAG-GACATCTGAGTCAGCTG-3', where the AP-1 site is indicated in bold italic. The mutated AP-1 probe contains G?A and C?G (underlined in one strand of the wild-type oligonucleotide) substitutions, which abolish the AP-1 binding.
In supershift assays 2 mg of either anti-Fos or anti-GAL4 antibodies (Santa Cruz Biotech. Inc., Santa Cruz, CA) or 2 ml of the puri®ed IgG fraction of anti-PML antibody were preincubated with the extracts for 10 min before the addition of double-stranded AP-1 labeled probe. In competition assays, 500 or 1000-fold molar excess of either wild-type or mutated double-stranded AP-1 oligonucleotide was preincubated with the extracts for 10 min before the addition of the labeled AP-1 double-stranded oligonucleotide. The IgG fraction of the anti-PML antibody (He et al., 1997) was puri®ed using the Econo-Pac serum IgG puri®cation chromatography columns following the manufacture's instruction (Bio-Rad Laboratories).
Immunoprecipitation/EMSA and Western blotting
In immunoprecipitation/EMSA experiments (Figure 5a ), approximately 400 mg of nuclear extracts from HeLa cells transiently overexpressing PML were incubated with antibodies against Jun or PML in 500 ml of wash buer containing 150 mM KCl at 48C overnight. The immunocomplexes were absorbed on protein-A agarose (Santa Cruz Biotech. Inc.) for 2 h at 48C and washed ®ve-times with wash buer containing 150 mM KCl. Associated proteins were eluted in 20 ml of nuclear extraction buer containing 0.5 mg/ml bovine serum albumin and 5 ml (*5 mg) of proteins was used for EMSA as described above.
Western blotting was performed on total proteins extracted from Cos-1 cells transiently transfected with pSG5PMLRARa. After transfection and treatment with dierent concentrations of ATRA for 24 h as indicated in Figure 3b , Cos-1 cells were washed in PBS and lysed in RIPA buer (140 mM NaCl, 27 mM KCl, 10 mM Na 2 HPO 4 , 18 mM KH 2 PO 4 , 1% Triton X-100, 13 mM sodium deoxycholate, 0.1% SDS, 1 mM EDTA, and protease inhibitors as above) for 20 min on ice. Approximately 100 mg of total extracts for each sample was resolved in an 8% SDS polyacrylamide gel, transferred to nitrocellulose membrane (Schleicher & Schuell Inc., Keene, NH), probed with anti-PML antibody and detected using the ECL system (Amersham Life Sciences Inc., Arlington Heights, IL).
In vitro translation and GST pull-down assay
The c-Fos and c-Jun proteins were expressed under the SP6 promoter and the PML and ATF2 proteins were driven by the T7 promoter using the TNT-coupled transcription/ translation system as outlined by the manufacturer (Promega Corp.), and labeled with 35 S-methionine. All proteins were in vitro translated individually. In coimmunoprecipitation experiments, as shown in Figure 5b , 5 ml of each in vitro translated proteins was incubated in 250 ml of RIPA buer in the presence of anti-PML antibody for 2 h at 48C. The immune complexes were then absorbed to protein-A agarose, washed three times in RIPA buer, boiled and subjected to an 8% SDS ± polyacrylamide gel electrophoresis (PAGE) as described above. The gel was vacuumdried and autoradiographed. The GST/PML fusion protein was produced as described in our previous report (He et al., 1997) . The GST pull-down assay was performed essentially as described previously (Hagemeier et al., 1993) . Brie¯y, GST and GST/PML proteins immobilized on glutathione agarose 4B beads (Sigma Chemical Co, St Louis, MO) were washed in NETN buer (100 mM NaCl, 1 mM EDTA, 20 mM Tris-HCl pH 8, 0.5% NP-40) and incubated with 5 ml of 35 S-methionine in vitro translated proteins in 200 ml of NETN buer for 1 h at room temperature on a rocker. The bound proteins were washed three times in 1 ml of NETN buer and eluted in SDS sample buer by boiling for 5 min. The eluted proteins were subjected to SDS ± PAGE as described above.
